Recent patents on ophthalmic nanoformulations and therapeutic implications

Recent Patents on Drug Delivery and Formulation

Volumn 8, Issue 3, 2014, Pages 193-201

  Ako Adounvo, Ann Marie ^a   Nagarwal, Ramesh C ^a   Oliveira, Lais ^a   Boddu, Sai H S ^b   Wang, Xiang S ^a   Dey, Surajit ^c   Karla, Pradeep K ^a  

^a HOWARD UNIVERSITY   (United States)

^b UNIVERSITY OF TOLEDO   (United States)

^c ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Calcium phosphate nanoparticles; Nanoemulsions; Nanomicelles; Ophthalmic bioavailability; Ophthalmic nanoformulations

Indexed keywords

BESIFLOXACIN; BETAMETHASONE; BIMATOPROST; BUDESONIDE; CEPHALOSPORIN; COUMARIN; CYCLOSPORIN A; DEXAMETHASONE; DORZOLAMIDE; EVEROLIMUS; GENTAMICIN; LATANOPROST; LIPOSOME; METHYLPREDNISOLONE; NANOPARTICLE; PIMECROLIMUS; POLIDRONIUM CHLORIDE; POLYCARBOPHIL; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS; TAFLUPROST; TEMSIROLIMUS; TIMOLOL MALEATE; TRAVOPROST; TRIAMCINOLONE; UNINDEXED DRUG; VOCLOSPORIN; ZOTAROLIMUS; DELAYED RELEASE FORMULATION; EYE DROPS;

ARTICLE; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG PENETRATION; HUMAN; HYDROGEL; MEAN RESIDENCE TIME; NANOEMULSION; NANOMEDICINE; NANOMICELLE; NONHUMAN; OPHTHALMIC NANOFORMULATION; PATENT; PRIORITY JOURNAL; PROTEIN BINDING; SOFT CONTACT LENS; SUSTAINED DRUG RELEASE; VISCOSITY; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; TRENDS;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PATENTS AS TOPIC;

EID: 84926394128     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872211308666140926112000     Document Type: Article

References (64)

1. Maurice DM, Mishima S. Ocular pharmacokinetics, In: Handbook of Experimental Pharmacology. Springler Verag, Berlin-Heidelberg 1989; 69: 16-119.
2. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Reviews 2006; 58: 1131-5.
3. Sterile ophthalmic gel forming solution TIMOPTIC-XE®. Available at: http://www.merck.com/product/usa/pi_circulars/t/timoptic/ timoptic_xe_pi.pdf. (Accessed on: May 13, 2013).
4. Kabra, B.P. Topical ophthalmic compositions containing tobramycin and dexamethasone. US7795316B1 (2010).
5. Lallemand, F., Daull, P., Benita, S., Buggage, R., Garrigue, J.S. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J Drug Deliv 2012; 2012: 604204.
6. Endres CJ, Hsiao P, Chung FS, Unadkat JD. The role of transporters in drug interactions. Eur J Pharm Sci 2006; 27: 507-17.
7. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters on drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 2012; 52: 249-73.
8. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J 2010; 12(3): 348-60.
9. Simonnet, J.T., Sonneville, O., Lagret, S. Nanoemulsion based on oxyethylenated or non-oxyethylated sorbiton fatty esters, and its use in the cosmetic, dermatological and/or ophthalmological fields. US6335022B1 (2002).
10. Simonnet, J.T., Sonneville, O., Lagret, S. Nanoemulsion based on ethoxylated fatty ethers or on ethoxylated fatty esters, and its use in the cosmetic, dermatological and/or ophthalmological fields. US6375960 (2002).
11. Swan KC. The use of methylcellulose in ophthalmology. Achieves Ophthalmol 1945; 3: 378-80.
12. L'Alloret, F., Sonneville, O., Simonnet, J.T. Nanoemulsion containing nonionic polymers, and its uses. US6998426 (2006).
13. Comments to CTAF on the Cost-Effectiveness of Sofosbuvir. Available at: https://masshealthdruglist.ehs.state.ma.us/MHDL/ pubtheradetail.do?id=52. (Accessed on: August 3, 2014).
14. Toris CB. Pharmacotherapies for glaucoma. Curr Mol Med 2010; 10(9): 824-40.
15. Carli, F., Baronian, M., Schmid, R., Chiellini, E. Ophthalmic oil-inwater emulsions containing prostaglandins. US8414904B2 (2013).
16. Kaswan, R. Ophthalmic treatment by topical administration of cyclosporine. US4649047 (1987).
17. Kawashima, Y., Kuwano, M. Cyclosporin compositions. US6582718 (2003).
18. Domb, A.J., Avramoff, A., Prevzner, V. Pro-nanodispersion for the delivery of cyclosporine. US7732404 (2010).
19. Rowe, RC, Sheskey PJ, Cook WG; Fenton ME. Handbook of Pharmaceutical Excipients 2003; 4.sup.th edition.
20. Benita, S., Elbaz, E. Oil-in-water emulsion of positively charged particles. US6007826 (1999).
21. Benita, S., Lambert, G. Method and composition for dry eye treatment. US6656460 (2003).
22. Bague, S., Betty, P., Garrigue, J.S., Guilatt, L.R., Lambert, G. Oilin-water type emulsion with low concentration of cationic agent and positive zeta potential. US8298568 (2012).
23. Kuno N, Fujii S. Recent advances in ocular drug delivery systems. Polymers 2011; 3: 193-221.
24. Novasorb® our topical technology platform. Available at: http://www.novagali.com/en/our-research/novasorb. (Accessed on: May 13, 2013).
25. Bague, S., Philips, B., Garrigue, J.S., Rabinovich-guilatt, L., Lambert, G. Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential. EP1655021 (2008).
26. Philips, B., Bague, S., Rabinovich-guilatt, L., Lambert, G. Ophthalmic emulsions containing an immunosuppressive agent. EP1809238 (2008).
27. Philips, B., Bague, S., Rabinovich-guilatt, L., Lambert, G. Ophthalmic emulsions containing prostaglandin. EP1827373 (2008).
28. Chauhan, A., Gulsen, D. Ophthalmic drug delivery system. US8273366 (2012).
29. Mitra, A.K., Velagaleti, P.R., Grau, U.M. Topical drug delivery for ophthalmic use. WO2010144194 (2010).
30. Gupta AK, Madan S, Majumdar DK, Maitra A. Ketorolac entrapped in polymeric micelles: Preparation, characterization and ocular anti-inflammatory studies. Int J Pharm 2000; 209: 1-14.
31. Velagaleti PR, Anglade E, Khan IJ, Gilger BC, Mitra AK. Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior and posterior segments of the eye. Drug Deliv Technol 2010; 10(4): 42-7.
32. Mitra, A.K., Velagaeti, P.R., Natesan, S. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors. US0092665 (2009).
33. Alexis, F., Zhang, L., Radovic-Moreno, A., Gu, F., Basto, P., Levy-Nissenbaum, E., Chan, J., Farokhzad, O. Poly (amino acid) targeting moieties. US20090074828A1 (2009).
34. Ravi, N. Hydrogel nanocompsites for ophthalmic applications. US8153156B2 (2012).
35. Ketelson, H.A., Dassanayake, N.L., Carey, T.C., Meadows, D. Use of nanoparticles as carriers for biocides in ophthalmic compositions. US8097270 (2012).
36. Chen R, Qian Y, Li R, Zhang Q, Liu D, Wang M, et al. Methazolamide calcium phosphate nanoparticles in a ocular delivery system. Pharm Soc Japan 2010; 130(3): 419-24.
37. Bell, S.T.D., Chu, T., He, Q., Potter, D.E. Intraocular delivery compositions and methods. WO2004050065A1 (2004).
38. Cheruvu NPS, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci 2008; 49(1): 333-41.
39. Chu TC, He Q, Potter DE. Biodegradable calcium phosphate nanoparticles as a new vehicle for delivery of a potential ocular hypotensive agent. J Ocul Pharmacol Ther 2002; 18(6): 507-14.
40. Chu E, Chu TC, Potter DE. Mechanisms and sites of ocular action of 7-hydroxy-2-dipropylaminotetralin: A dopamine (3) receptor agonist. J Pharmacol Exp Ther 2000; 293(3): 710-6.
41. Edelhauser HF, Rowe-Rendleman C, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: Basic research to clinical applications. Invest Ophthalmol Vis Sci 2010; 51(11): 5403-20.
42. Hu J, Kovtun A, Tomaszewski A, Singer BB, Seitz B, Epplec M, et al. A new tool for the transfection of corneal endothelial cells: Calcium phosphate nanoparticles. Acta Biomater 2012; 8: 1156-63.
43. Sokolova VV, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006; 27: 3147-53.
44. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies. (AAPS) Pharm Sci Tech 2007; 8(1): 1.
45. Bourges JL, Touchard E, Kowalczuk L, Berdugo M, Thomas-Doyle A, Bochot A, et al. Drug delivery systems for intraocular applications. J Fr Ophtalmol 2007; 30(10): 1070-88.
46. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: An overview. Int J Pharm 2004; 269(1): 1-14.
47. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol 2005; 50(2):167-82.
48. Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv 2011; 1-14.
49. Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci 1982; 22(2): 220-7.
50. Fitzgerald P, Hadgraft J, Wilson CG. A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit. J Pharm Pharmacol 1987; 39(6): 487-90.
51. Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular delivery system: Physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm; 36(1): 108-18.
52. Bochot A, Fattal E, Boutet V, Deverre JR, Jeanny JC, Chacun H, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Inv Ophthalmol Vis Sci 2002; 43: 253-9.
53. Guo, L.S.S., Redmann, C.T., Radhakrishnan, R. Ophthalmic liposomes. US4804539 (1989).
54. Hofland, H., Bongianni, J., Wheeler, T. Ophthalmic liposome compositions and uses thereof. US20040224010 (2004).
55. Liu, Y., Lu, P.Y., Woodle, M.C., Xie, F.Y. Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases. US7893244 (2011).
56. Hara, H.N., Takeuchi, H.G. Liposome for delivery to posterior segment of eye and pharmaceutical composition for disease in posterior segment of eye. US20110008421 (2011).
57. Kato, M., Ohtsuki, T., Egami, F., Tsunoda, K. Liposome eye drops. US5945121 (1999).
58. Zeimer, R. Selective and non-invasive visualization or treatment of vasculature. US6440950 (2002).
59. Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS. Nanomedicine for glaucoma: Liposomes provide sustained release of latanoprost in the eye. Int J Nanomed 2012; 7: 123-31.
60. Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes. Pharm Dev Technol 2011; 16(1): 44-56.
61. Shafaa MW, Sabra NM, Fouad RA. The extended ocular hypotensive effect of positive liposomal cholesterol bound timolol maleate in glaucomatous rabbits. Biopharm Drug Dispos 2011; 32(9): 507-17.
62. Ammar HO, Salama HA, Ghorab, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS Pharm Sci Tech 2009; 10(3): 808-19.
63. Dry eye therapy utilizing cationic Novasorb® technology available soon from OCuSOFT®. Available at: http://www.prnewswire.com/news-releases/dry-eye-therapy-utilizing-cationic-novasorb-technology-available-soon-from-ocusoft-123820724.html. (Accessed on: May 21, 2014).
64. InSite vision introduces DuraSite2® ophthalmic drug delivery system. Available at: http://phx.corporateir.net/phoenix.zhtml?c=86061&p=irolnewsArticle&ID=1731615&highlight. (Accessed on: May 17, 2014).